The effect of completeness of revascularization on event-free survival at one year in the arts trial
Marcel J. B. M. van den Brand, MD*,*,
Benno J. W. M. Rensing, MD*,
Marie-angèle M. Morel, BSc
,
David P. Foley, MD*,
Vincent de Valk, PhD
,
Arno Breeman, MD
,
Harry Suryapranata, MD, FACC
,
Maximiliaan M. P. Haalebos, MD
,
William Wijns, MD
,
Francis Wellens, MD
,
Rafael Balcon, MD, FACC||,
Patrick Magee, MD, FACC||,
Expedito Ribeiro, MD¶,
Enio Buffolo, MD¶,
Felix Unger, MD, FACC# and
Patrick W. Serruys, MD, FACC*
* Thoraxcenter, Department of Cardiology, University Hospital Dijkzigt, Rotterdam, The Netherlands
Cardialysis, Rotterdam, The Netherlands
Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
|| London Chest Hospital, London, United Kingdom
¶ Incor, The Heart Institute of the University of São Paulo, São Paulo, Brazil
# Klinik für Herzchirurgie, Landeskliniken, Salzburg, Austria

View larger version (33K):
[in a new window]
|
Figure 1 (A) Freedom from death, myocardial infarction (MI) or cerebrovascular accident (CVA) within one year, after complete or incomplete revascularization with coronary artery bypass graft surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) stenting. (B) Event-free survival in the four subgroups, also including repeat revascularization as an event.
|
|
Copyright © 2002 by the American College of Cardiology Foundation.